

Jamie N Bakkum-Gamez

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/966060/publications.pdf>

Version: 2024-02-01

100
papers

3,322
citations

126907

33
h-index

161849

54
g-index

100
all docs

100
docs citations

100
times ranked

4568
citing authors

#	ARTICLE	IF	CITATIONS
1	Targeting LRRC15 Inhibits Metastatic Dissemination of Ovarian Cancer. <i>Cancer Research</i> , 2022, 82, 1038-1054.	0.9	26
2	The cost of diagnosing endometrial cancer: Quantifying the healthcare cost of an abnormal uterine bleeding workup. <i>Gynecologic Oncology</i> , 2022, 164, 93-97.	1.4	6
3	Methylated DNA markers for plasma detection of ovarian cancer: Discovery, validation, and clinical feasibility. <i>Gynecologic Oncology</i> , 2022, 165, 568-576.	1.4	10
4	Protocol for the Detection of Organoid-Initiating Cell Activity in Patient-Derived Single Fallopian Tube Epithelial Cells. <i>Methods in Molecular Biology</i> , 2022, 2429, 445-454.	0.9	2
5	Human Papillomavirus-Associated Anogenital Pathology in Females With HPV-Positive Oropharyngeal Squamous Cell Carcinoma. <i>Otolaryngology - Head and Neck Surgery</i> , 2021, 164, 369-374.	1.9	2
6	Development of novel home-based tampon sampling for endometrial cancer: findings from community-based focus groups with Black and White women. <i>Journal of Clinical and Translational Science</i> , 2021, 5, e125.	0.6	2
7	Disparities and interventions in the timeliness of endometrial cancer diagnosis and treatment in the United States: a scoping review protocol. <i>Systematic Reviews</i> , 2021, 10, 107.	5.3	4
8	PP2A and E3 ubiquitin ligase deficiencies: Seminal biological drivers in endometrial cancer. <i>Gynecologic Oncology</i> , 2021, 162, 182-189.	1.4	6
9	Quantifying procedural pain associated with office gynecologic tract sampling methods. <i>Gynecologic Oncology</i> , 2021, 162, 128-133.	1.4	6
10	Tao brush endometrial cytology is a sensitive diagnostic tool for cancer and hyperplasia among women presenting to clinic with abnormal uterine bleeding. <i>Cancer Medicine</i> , 2021, 10, 7040-7047.	2.8	8
11	Association of a novel endometrial cancer biomarker panel with prognostic risk, platinum insensitivity, and targetable therapeutic options. <i>PLoS ONE</i> , 2021, 16, e0245664.	2.5	5
12	A case of a large leiomyomatous uterus with multiple arteriovenous malformations and subsequent high cardiac output state with severe four chamber cardiac enlargement. <i>Gynecologic Oncology Reports</i> , 2021, 38, 100898.	0.6	0
13	Analysis of DNA methylation in endometrial biopsies to predict risk of endometrial cancer. <i>Gynecologic Oncology</i> , 2020, 156, 682-688.	1.4	20
14	Predictive Blood-Based Biomarkers in Patients with Epithelial Ovarian Cancer Treated with Carboplatin and Paclitaxel with or without Bevacizumab: Results from GOG-0218. <i>Clinical Cancer Research</i> , 2020, 26, 1288-1296.	7.0	29
15	A prospective clinical cohort study of women at increased risk for endometrial cancer. <i>Gynecologic Oncology</i> , 2020, 156, 169-177.	1.4	17
16	Combining copy number, methylation markers, and mutations as a panel for endometrial cancer detection via intravaginal tampon collection. <i>Gynecologic Oncology</i> , 2020, 156, 387-392.	1.4	22
17	In Reply. <i>Obstetrics and Gynecology</i> , 2020, 136, 424-425.	2.4	0
18	Vaginal Hysterectomy: Historical Footnote or Viable Route?. <i>Obstetrics and Gynecology</i> , 2020, 136, 426-426.	2.4	1

#	ARTICLE	IF	CITATIONS
19	Retained Products of Conception After Cesarean Section and Occult Placenta Accreta. <i>Mayo Clinic Proceedings</i> , 2020, 95, 2462-2463.	3.0	2
20	Is hormonal therapy after risk-reducing salpingo-oophorectomy associated with an increased risk of malignancy in pathogenic variant carriers?. <i>Gynecologic Oncology</i> , 2020, 157, 706-710.	1.4	0
21	When to Operate, Hesitate and Reintegrate: Society of Gynecologic Oncology Surgical Considerations during the COVID-19 Pandemic. <i>Gynecologic Oncology</i> , 2020, 158, 236-243.	1.4	42
22	Intercepting Endometrial Cancer: Opportunities to Expand Access Using New Technology. <i>Cancer Prevention Research</i> , 2020, 13, 563-568.	1.5	6
23	Ultrasound detection of endometrial cancer in women with postmenopausal bleeding: Systematic review and meta-analysis. <i>Gynecologic Oncology</i> , 2020, 157, 624-633.	1.4	29
24	Risk assessment of endometrial cancer and endometrial intraepithelial neoplasia in women with abnormal bleeding and implications for clinical management algorithms. <i>American Journal of Obstetrics and Gynecology</i> , 2020, 223, 549.e1-549.e13.	1.3	40
25	Multidisciplinary management of extensive intravenous leiomyomatosis: A coordinated effort of a single institution. <i>Gynecologic Oncology Reports</i> , 2020, 32, 100557.	0.6	2
26	Invasive vulvar extramammary Paget's disease in the United States. <i>Gynecologic Oncology</i> , 2020, 157, 649-655.	1.4	17
27	Comparing risk stratification criteria for predicting lymphatic dissemination in endometrial cancer. <i>Gynecologic Oncology</i> , 2019, 155, 21-26.	1.4	11
28	Leiomyoma with KAT6B-KANSL1 fusion: case report of a rapidly enlarging uterine mass in a postmenopausal woman. <i>Diagnostic Pathology</i> , 2019, 14, 32.	2.0	11
29	Quality improvement in gynecologic oncology: Current successes and future promise. <i>Gynecologic Oncology</i> , 2019, 152, 486-491.	1.4	16
30	Lymphadenectomy in the Management of Gynecologic Cancer. <i>Clinical Obstetrics and Gynecology</i> , 2019, 62, 749-755.	1.1	3
31	Beyond prophylaxis: Extended risk of venous thromboembolism following primary debulking surgery for ovarian cancer. <i>Gynecologic Oncology</i> , 2019, 152, 286-292.	1.4	26
32	Cancer susceptibility gene mutations in type I and II endometrial cancer. <i>Gynecologic Oncology</i> , 2019, 152, 20-25.	1.4	32
33	Mesenchymal molecular subtype is an independent predictor of severe postoperative complications after primary debulking surgery for advanced ovarian cancer. <i>Gynecologic Oncology</i> , 2019, 152, 223-227.	1.4	17
34	Increasing genetic counseling referral rates through bundled interventions after ovarian cancer diagnosis. <i>Gynecologic Oncology</i> , 2018, 149, 121-126.	1.4	15
35	Quinacrine upregulates p21/p27 independent of p53 through autophagy-mediated downregulation of p62-Skp2 axis in ovarian cancer. <i>Scientific Reports</i> , 2018, 8, 2487.	3.3	51
36	Uterine serous carcinoma: Reassessing effectiveness of platinum-based adjuvant therapy. <i>Gynecologic Oncology</i> , 2018, 149, 291-296.	1.4	12

#	ARTICLE	IF	CITATIONS
37	Estimated Blood Loss During Vaginal Hysterectomy and Adnexal Surgery Described With an Intraoperative Pictographic Tool. <i>Female Pelvic Medicine and Reconstructive Surgery</i> , 2018, 24, 347-351.	1.1	3
38	Criteria for Risk Stratification of Vulvar and Vaginal Smooth Muscle Tumors. <i>American Journal of Surgical Pathology</i> , 2018, 42, 84-94.	3.7	34
39	Opportunistic salpingectomy to decrease the mortality from ovarian cancer: Can we expand the pool of eligible patients?. <i>Surgery</i> , 2018, 164, 935-936.	1.9	3
40	Factors that influence survival in high-grade serous ovarian cancer: A complex relationship between molecular subtype, disease dissemination, and operability. <i>Gynecologic Oncology</i> , 2018, 150, 227-232.	1.4	40
41	Association of Endometrial Cancer Risk With Postmenopausal Bleeding in Women. <i>JAMA Internal Medicine</i> , 2018, 178, 1210.	5.1	233
42	Evidence-Based Screening Recommendations for Occult Cancers in the Setting of Newly Diagnosed Extramammary Paget Disease. <i>Mayo Clinic Proceedings</i> , 2018, 93, 877-883.	3.0	29
43	Efforts at maximal cytoreduction improve survival in ovarian cancer patients, even when complete gross resection is not feasible. <i>Gynecologic Oncology</i> , 2017, 145, 21-26.	1.4	58
44	Factors associated with deciding between risk-reducing salpingo-oophorectomy and ovarian cancer screening among high-risk women enrolled in GOG-0199: An NRG Oncology/Gynecologic Oncology Group study. <i>Gynecologic Oncology</i> , 2017, 145, 122-129.	1.4	21
45	Cost-effectiveness of opportunistic salpingectomy for ovarian cancer prevention. <i>Gynecologic Oncology</i> , 2017, 146, 373-379.	1.4	45
46	Venous Thromboembolism. <i>Obstetrics and Gynecology</i> , 2017, 129, 971-973.	2.4	1
47	Patterns of Lymph Node Metastases in Apparent Stage I Low-Grade Epithelial Ovarian Cancer: A Multicenter Study. <i>Annals of Surgical Oncology</i> , 2017, 24, 2720-2726.	1.5	44
48	In Reply. <i>Obstetrics and Gynecology</i> , 2017, 130, 914-915.	2.4	0
49	A matter of margins: Surgical and pathologic risk factors for recurrence in extramammary Paget's disease. <i>Gynecologic Oncology</i> , 2017, 147, 358-363.	1.4	38
50	Concomitant venous thromboembolism at the time of primary EOC diagnosis: Perioperative outcomes and survival analyses. <i>Gynecologic Oncology</i> , 2017, 147, 514-520.	1.4	6
51	Intraperitoneal disease dissemination patterns are associated with residual disease, extent of surgery, and molecular subtypes in advanced ovarian cancer. <i>Gynecologic Oncology</i> , 2017, 147, 503-508.	1.4	36
52	Comparison of a sentinel lymph node mapping algorithm and comprehensive lymphadenectomy in the detection of stage IIIC endometrial carcinoma at higher risk for nodal disease. <i>Gynecologic Oncology</i> , 2017, 147, 541-548.	1.4	82
53	Management of Breast Cancer Risk in Women with Ovarian Cancer and Deleterious BRCA1 or BRCA2 Mutations. <i>Annals of Surgical Oncology</i> , 2017, 24, 3107-3109.	1.5	4
54	Functional not chronologic age: Frailty index predicts outcomes in advanced ovarian cancer. <i>Gynecologic Oncology</i> , 2017, 147, 104-109.	1.4	92

#	ARTICLE	IF	CITATIONS
55	Pathologic findings in breast, fallopian tube, and ovary specimens in non- BRCA hereditary breast and/or ovarian cancer syndromes: a study of 18 patients with deleterious germline mutations in RAD51C , BARD1 , BRIP1 , PALB2 , MUTYH , or CHEK2. <i>Human Pathology</i> , 2017, 70, 14-26.	2.0	11
56	Improving Surgical Site Infection Rates Through Continuous Quality Improvement. <i>Annals of Surgical Oncology</i> , 2017, 24, 305-307.	1.5	3
57	Safety, pharmacokinetics, metabolism and radiation dosimetry of 18F-tetrafluoroborate (18F-TFB) in healthy human subjects. <i>EJNMMI Research</i> , 2017, 7, 90.	2.5	25
58	Ureteral obstruction in cancer patients: a qualitative study. <i>Psycho-Oncology</i> , 2016, 25, 605-609.	2.3	3
59	Options in Prophylactic Surgery to Prevent Ovarian Cancer in High-Risk Women: How New Hypotheses of Fallopian Tube Origin Influence Recommendations. <i>Current Treatment Options in Oncology</i> , 2016, 17, 20.	3.0	8
60	Refining the Definition of Low-Risk Endometrial Cancer: Improving Value. <i>Gynecologic Oncology</i> , 2016, 141, 189-190.	1.4	3
61	Muscle composition measured by CT scan is a measurable predictor of overall survival in advanced ovarian cancer. <i>Gynecologic Oncology</i> , 2016, 142, 311-316.	1.4	103
62	The effect of diabetes and metformin on clinical outcomes is negligible in risk-adjusted endometrial cancer cohorts. <i>Gynecologic Oncology</i> , 2016, 140, 270-276.	1.4	38
63	Comparison of a sentinel lymph node and a selective lymphadenectomy algorithm in patients with endometrioid endometrial carcinoma and limited myometrial invasion. <i>Gynecologic Oncology</i> , 2016, 140, 394-399.	1.4	139
64	Risk-prediction model of severe postoperative complications after primary debulking surgery for advanced ovarian cancer. <i>Gynecologic Oncology</i> , 2016, 140, 15-21.	1.4	80
65	Cervical Lipoleiomyoma: Transvaginal Approach for Excision. <i>Journal of Gynecologic Surgery</i> , 2015, 31, 370-372.	0.1	1
66	Abdominopelvic inflammatory myofibroblastic tumor that metastasized to the vertebrae and liver: A case report and review of the literature. <i>Gynecologic Oncology Reports</i> , 2015, 12, 9-12.	0.6	7
67	Surgical site infection after primary surgery for epithelial ovarian cancer: Predictors and impact on survival. <i>Gynecologic Oncology</i> , 2015, 136, 278-284.	1.4	39
68	Assessment of published models and prognostic variables in epithelial ovarian cancer at Mayo Clinic. <i>Gynecologic Oncology</i> , 2015, 137, 77-85.	1.4	15
69	Development of a prediction model for residual disease in newly diagnosed advanced ovarian cancer. <i>Gynecologic Oncology</i> , 2015, 138, 70-77.	1.4	40
70	Risk-adjusted outcomes in elderly endometrial cancer patients: Implications of the contrasting impact of age on progression-free and cause-specific survival. <i>Gynecologic Oncology</i> , 2015, 138, 133-140.	1.4	14
71	Detection of endometrial cancer via molecular analysis of DNA collected with vaginal tampons. <i>Gynecologic Oncology</i> , 2015, 137, 14-22.	1.4	79
72	Vaginal brachytherapy for early-stage carcinosarcoma of the uterus. <i>Brachytherapy</i> , 2015, 14, 433-439.	0.5	12

#	ARTICLE	IF	CITATIONS
73	Randomized Phase III Trial of Gemcitabine Plus Docetaxel Plus Bevacizumab or Placebo As First-Line Treatment for Metastatic Uterine Leiomyosarcoma: An NRG Oncology/Gynecologic Oncology Group Study. <i>Journal of Clinical Oncology</i> , 2015, 33, 1180-1185.	1.6	107
74	Targeted deep sequencing of mucinous ovarian tumors reveals multiple overlapping RAS-pathway activating mutations in borderline and cancerous neoplasms. <i>BMC Cancer</i> , 2015, 15, 415.	2.6	116
75	Repurposing the vaginal tampon for endometrial cancer detection. <i>Biomarkers in Medicine</i> , 2015, 9, 715-717.	1.4	3
76	Hypersensitivity to nickel in a patient treated with coil embolization for pelvic congestion syndrome. <i>Journal of Vascular Surgery: Venous and Lymphatic Disorders</i> , 2015, 3, 319-321.	1.6	14
77	Oncolytic Measles Virus Expressing the Sodium Iodide Symporter to Treat Drug-Resistant Ovarian Cancer. <i>Cancer Research</i> , 2015, 75, 22-30.	0.9	157
78	Preserving fertility in young patients with endometrial cancer: current perspectives. <i>International Journal of Women's Health</i> , 2014, 6, 691.	2.6	40
79	Pancreaticoduodenectomy in optimal primary cytoreduction of epithelial ovarian cancer: A case report and review of the literature. <i>Gynecologic Oncology Reports</i> , 2014, 10, 25-27.	0.6	3
80	Retooling the Pap Smear for Ovarian and Endometrial Cancer Detection. <i>Clinical Chemistry</i> , 2014, 60, 22-24.	3.2	12
81	Risk-scoring models for individualized prediction of overall survival in low-grade and high-grade endometrial cancer. <i>Gynecologic Oncology</i> , 2014, 133, 485-493.	1.4	64
82	Efficacy of contemporary chemotherapy in stage IIIC endometrial cancer: A histologic dichotomy. <i>Gynecologic Oncology</i> , 2014, 132, 578-584.	1.4	33
83	Discovery and validation of methylation markers for endometrial cancer. <i>International Journal of Cancer</i> , 2014, 135, 1860-1868.	5.1	62
84	Oncolytic vaccinia virotherapy for endometrial cancer. <i>Gynecologic Oncology</i> , 2014, 132, 722-729.	1.4	14
85	Prospective assessment of the prevalence of pelvic, paraaortic and high paraaortic lymph node metastasis in endometrial cancer. <i>Gynecologic Oncology</i> , 2014, 132, 38-43.	1.4	160
86	Effect of tubal sterilization technique on risk of serous epithelial ovarian and primary peritoneal carcinoma. <i>Gynecologic Oncology</i> , 2014, 135, 423-427.	1.4	97
87	Impact of obesity on surgical and oncologic outcomes in ovarian cancer. <i>Gynecologic Oncology</i> , 2014, 135, 19-24.	1.4	49
88	Oncolytic measles and vesicular stomatitis virotherapy for endometrial cancer. <i>Gynecologic Oncology</i> , 2014, 132, 194-202.	1.4	24
89	Impact of tubal ligation on routes of dissemination and overall survival in uterine serous carcinoma. <i>Gynecologic Oncology</i> , 2013, 128, 71-76.	1.4	8
90	Predictors and costs of surgical site infections in patients with endometrial cancer. <i>Gynecologic Oncology</i> , 2013, 130, 100-106.	1.4	72

#	ARTICLE	IF	CITATIONS
91	Conservative Management of Atypical Hyperplasia and Grade I Endometrial Carcinoma: Review of the Literature and Presentation of a Series. <i>Journal of Gynecologic Surgery</i> , 2012, 28, 262-269.	0.1	9
92	Incidence of and risk factors for postoperative ileus in women undergoing primary staging and debulking for epithelial ovarian carcinoma. <i>Gynecologic Oncology</i> , 2012, 125, 614-620.	1.4	28
93	Challenges in the Gynecologic Care of Premenopausal Women With Breast Cancer. <i>Mayo Clinic Proceedings</i> , 2011, 86, 229-240.	3.0	18
94	The impact of surgical guidelines and periodic quality assessment on the staging of endometrial cancer. <i>Gynecologic Oncology</i> , 2011, 123, 58-64.	1.4	34
95	Is There a High-Risk Subgroup of Stage I Epithelial Ovarian Cancer That Is Most Likely to Benefit From 6 Versus 3 Cycles of Adjuvant Chemotherapy?. <i>International Journal of Gynecological Cancer</i> , 2010, 20, 1125-1131.	2.5	6
96	Random peritoneal biopsies have limited value in staging of apparent early stage epithelial ovarian cancer after thorough exploration. <i>Gynecologic Oncology</i> , 2009, 115, 86-89.	1.4	35
97	Influence of Intraoperative Capsule Rupture on Outcomes in Stage I Epithelial Ovarian Cancer. <i>Obstetrics and Gynecology</i> , 2009, 113, 11-17.	2.4	83
98	MÄ¼llerian inhibiting substance type II receptor (MISIIR): A novel, tissue-specific target expressed by gynecologic cancers. <i>Gynecologic Oncology</i> , 2008, 108, 141-148.	1.4	56
99	Current Issues in the Management of Endometrial Cancer. <i>Mayo Clinic Proceedings</i> , 2008, 83, 97-112.	3.0	128
100	#GeneticTesting: Using Social Media to Facilitate Communication about testing to Women (Preprint). <i>JMIR Formative Research</i> , 0, , .	1.4	3